Cysteine-Conjugated Metabolites of Ginger Components, Shogaols, Induce Apoptosis through Oxidative Stress-Mediated p53 Pathway in Human Colon Cancer Cells

Junsheng Fu,† Huadong Chen,†,§ Dominique N. Soroka,†,§ Renaud F. Warin,† and Shengmin Sang*,†,‡

Abstract: Shogaols, the major constituents of thermally processed ginger, have been proven to be highly effective anticancer agents. Our group has identified cysteine-conjugated shogaols (M2, M2′, and M2″) as the major metabolites of [6]-, [8]-, and [10]-shogaol in human and found that M2 is a carrier of its parent molecule [6]-shogaol in cancer cells and in mice, while being less toxic to normal colon fibroblast cells. The objectives of this study are to determine whether M2′ and M2″ behave in a similar manner to M2, in both metabolism and efficacy as anticancer agents, and to further explore the biological pro-apoptotic mechanisms of the cysteine-conjugated shogaols against human colon cancer cells HCT-116 and HT-29. Our results show that [8]- and [10]-shogaol have similar metabolic profiles to [6]-shogaol and exhibit similar toxicity toward human colon cancer cells. M2′ and M2″ both show low toxicity against normal colon cells but retain potency against colon cancer cells, suggesting that they have similar activity to M2. We further demonstrate that the cysteine-conjugated shogaols can cause cancer cell death through the activation of the mitochondrial apoptotic pathway. Our results show that oxidative stress activates a p53 pathway that ultimately leads to p53 up-regulated modulator of apoptosis (PUMA) induction and down-regulation of B-cell lymphoma 2 (Bel-2), followed by cytochrome c release, perturbation of inhibitory interactions of X-linked inhibitor of apoptosis protein (XIAP) with caspases, and finally caspase 9 and 3 activation and cleavage. A brief screen of the markers attenuated by the proapoptotic activity of M2 revealed similar results for [8]- and [10]-shogaol and their respective cysteine-conjugated metabolites M2′ and M2″. This study highlights the cysteine-conjugated metabolites of shogaols as novel dietary colon cancer preventive agents.

Keywords: ginger, cysteine-conjugated metabolites, shogaols, colon cancer, apoptosis

Introduction

Ginger, the rhizome of Zingiber officinale, has been cultivated as both a ubiquitous spice and a traditional medicinal food for thousands of years. Its many curative properties include treatment of nausea and dyspepsia, ameliorating symptoms of arthritis via anti-inflammation, and therapeutic activity against asthma, respiratory disorders, and rheumatic ailments. Most recently, pharmacologically active components of ginger have been implicated in chemoprevention via numerous mechanisms. Gingerols and shogaols have been identified as the most active ingredients in ginger. Shogaols, the products of ginger thermal processing, consistently show greater anticarcinogenic activity than gingerols, with [6]-shogaol (6S) being the most abundant one followed by [10]- and [8]-shogaol (10S and 8S) (Figure 1A). In particular, 6S has repeatedly shown strong chemopreventive activity against colorectal cancer, the third most common cancer diagnosed in the United States. Therapeutics with high anticancer potency often come under scrutiny for their accompanying toxicity against noncancerous cells in the viable organism. Consequently, there is escalating interest in employing dietary components and their metabolic constituents as less noxious treatments toward chemoprevention. Our group has recently established that the reactive ginger component 6S is extensively metabolized in mice and in cancer cells and that redox transformation and a phase II mercapturic acid pathway (MAP) are its major metabolic routes. As previously reported, an initial reaction between the α,β-unsaturated ketone functional group of 6S and the cysteine sulfhydryl component of GSH takes place in the MAP, giving rise to the corresponding conjugates. The conjugates then undergo series of enzymatic modifications on the GSH moiety, forming cysteinylglycine, cysteine, and finally N-acetylcysteine conjugates. Additional studies show that both 8S and 10S are also metabolized in humans through the MAP and the cysteine-conjugated metabolites, M2′ and M2″, respectively (Figure 1B), were identified as their major metabolites in human urine. Phase II metabolism products such as thiol conjugates are more water-soluble and often less toxic and pungent than their parent compounds, making them preferable for chemoprevention trials. Our group recently investigated the bioactivity of the cysteine-conjugated metabolite of [6]-shogaol (M2) and its putative mode of action as a hydrophilic carrier of the parent molecule to its site of efficacy. We established that cysteine-conjugation reduced the toxicity of 6S against normal human colon and lung fibroblast cells while
still retaining efficacy against human colon and lung cancer cells. Through a series of chemical stability and biological assays, we demonstrated the function of M2 as a carrier of 6S to its active site, wherein the parent compound is rendered less toxic but regains potency and similar bioactivity upon deconjugation. It is still unknown whether M2′ and M2″ behave in a similar manner to M2, in both efficacy as anticancer agents and metabolically. As an expansion of our proposed chemical mechanism for cysteine conjugates as carriers of their parent molecule shogaols, we investigated whether M2′ and M2″ are the respective carriers of 8S and 10S in cancer cells and can induce apoptosis through a mechanism similar to M2.

Although we have established the functionality and importance of M2, its mechanism of action against colon cancer cells has not been completely elucidated. There have been studies implicating 6S as a pro-apoptotic agent, via reactive oxygen species (ROS) production and subsequent growth arrest and DNA damage (GADD)-inducible transcription factor 153 (GADD153) expression in COLO 205 growth arrest and DNA damage (GADD)-inducible reactive oxygen species (ROS) production and subsequent bioactivity of M2, M2′, or M2″ is dependent upon p53 status is of critical concern in terms of cancer prevention, since usable compounds must be able to exert their activity through the early mutations stages of cancer.

## MATERIALS AND METHODS

### Cell Culture

HCT-116 and HT-29 human colon cancer cells, CCD-18Co human fibroblast cells derived from colon, and Eagle’s minimum essential media (EMEM) were obtained from American Type Tissue Culture (Manassas, VA). McCoy’s 5A medium was purchased from Thermo Fisher Scientific (Waltham, MA). Supplements of fetal bovine serum (FBS) and penicillin/streptomycin were purchased from Gemini Bio-Products (West Sacramento, CA).

### Reagents

6S, 8S, and 10S were purified from ginger extract in our laboratory. M2 was synthesized in our laboratory, as previously reported. HPLC-grade solvents and other reagents were obtained from VWR International (South Plainfield, NJ). LC/MS grade solvents and other reagents were obtained from Thermo Fisher Scientific (Rockford, IL). Glutathione was obtained from Sigma-Aldrich (St. Louis, MN). Crystal violet, glutaraldehyde, MTT [3-(4,5-dimethylthiaxol-2-y)-2,5-diphenyltetrazolium bromide], and propidium iodide were procured from Thermo Fisher Scientific (Waltham, MA). Primary antibodies against β-actin, B-cell lymphoma 2 (Bcl-2), caspase 9, caspase 3, cytochrome c, PUMA (p53 up-regulated modulator of apoptosis), p53, XIAP (X-linked inhibitor of apoptosis protein), as well as secondary antibodies conjugated to HRP (horseradish peroxidase) against mouse and rabbit were purchased from Cell Signaling Technology (Beverly, MA).

### HPLC-ECD Analysis

A high-performance liquid chromatography/ESA electrochemical detector (HPLC-ECD) (ESA, Chelmsford, MA) consisting of an ESA model 584 HPLC pump, an ESA model 542 autosampler, an ESA organizer, and an ESA electrochemical detector (ECD) coupled with two ESA model 6210 four sensor cells was used. A Gemini C18 column (150 mm × 4.6 mm, 5 μm; Phenomenex, Torrance, CA) was used for chromatographic analysis at
Table 1. δ_H (600 MHz) and δ_C (150 MHz) NMR Spectra Data of M2’ and M2″

|        | M2’   |        | M2″   |
|--------|-------|--------|-------|
| δ_H mult (J) | δ_C   | δ_H mult (J) | δ_C   |
| 1      | 2.81, m | 31.6   | 2.81, m | 31.8  |
| 2      | 2.81, m | 48.1   | 2.81, m | 48.1  |
| 3      |        | 210.4  |        | 210.4 |
| 4      | 2.81, m | 53.8   | 2.81, m | 53.8  |
| 5      | 3.11, m | 40.9   | 3.11, m | 40.9  |
| 6      | 1.56, m | 34.9   | 1.56, m | 34.9  |
| 7      | 1.42, m | 27.4   | 1.42, m |       |
| 8      | 1.31, m | 31.8   | 1.31, m | 31.8  |
| 9      | 1.31, m | 292.4  | 1.31, m | 29.3  |
| 10     | 1.31, m | 28.96  | 1.31, m | 29.3  |
| 11     | 1.31, m | 28.96  | 1.31, m | 29.2  |
| 12     | 1.31, m | 26.4a  | 1.31, m | 29.1  |
| 13     | 0.92, t (6.9) | 22.3 | 1.31, m | 28.9  |
| 14     | 13.0   |        | 1.31, m | 26.4  |
| 15     | 1.31, m |       |       | 22.3  |
| 16     | 0.92, t (6.9) | 13.0 |       |       |
| 1’     | 132.4  |        |       |       |
| 2’     | 6.80, d (2.0) | 111.7 | 6.80, d (2.0) | 111.8 |
| 3’     | 147.8  |        |       |       |
| 4’     | 144.4  |        |       |       |
| 5’     | 6.71, d (7.98) | 115.0 | 6.71, d (7.98) | 115.0 |
| 6’     | 6.65, dd (7.98, 2.0) | 120.4 | 6.65, dd (7.98, 2.0) | 120.5 |
| 1”     | (a) 3.21, m | 32.0 | (a) 3.21, m | 32.1  |
|        | (b) 2.81, m |       | (b) 2.81, m |       |
| 2”     | 3.66, m | 54.9   | 3.66, m | 54.9  |
| 3”     | 171.1  |        | 171.2  |       |
| OMe    | 3.85, s | 55.1   | 3.85, s | 55.0  |

| a | CD3OD; δ in ppm and J in Hz. b Assignments interchangeable. |

A flow rate of 1.0 mL/min. The mobile phases consisted of solvent A (30 mM sodium phosphate buffer containing 1.75% ACN and 0.125% THF, pH 3.35) and solvent B (15 mM sodium phosphate buffer containing 58.5% ACN and 12.5% THF, pH 3.45). The gradient elution had the following profile: 20% B from 0 to 3 min; 20–55% B from 3 to 11 min; 55–60% B from 11 to 12 min; 60–65% B from 12 to 13 min; 65–100% B from 13 to 40 min; 100% B from 40 to 45 min; then 20% B from 45.1 to 50 min. The cells were then cleaned at a flow rate of 4.0 mL/min. The column was then re-equilibrated with 100% A for 5 min. The LC eluent was introduced into the H-ESI formic acid) and solvent B (MeOH + 0.1% formic acid) for 3 min, followed by linear increases in B (95% aqueous methanol with 0.2% acetic acid) to 40% from 3 to 15 min, to 91% from 15 to 49 min, and to 100% from 49 to 50 min, and then with 100% B from 50 to 55 min. The column was then re-equilibrated with 100% A for 5 min. The LC eluent was introduced into the H-ESI interface. The positive ion polarity mode was set for the H-ESI source with the voltage on the H-ESI interface maintained at approximately 4.5 kV. Nitrogen gas was used as the sheath gas and auxiliary gas. Optimized source parameters, including ESI capillary temperature (300 °C), capillary voltage (50 V), ion spray voltage (3.6 kV), sheath gas flow rate (30 units), auxiliary gas flow rate (5 units), and tube lens (120 V), were tuned using authentic 6S. The collision-induced dissociation (CID) was conducted with an isolation width of 2 Da and normalized collision energy of 35 for MS2 and MS3. Default automated gain control target ion values were used for MS2–MS3 analyses. The mass range was measured from 50 to 1000 m/z. Data acquisition was performed with Xcalibur 2.0 version (Thermo Electron, San Jose, CA).

Chemical Synthesis of M2’ and M2″. The experimental procedure to synthesize M2’ and M2″ was similar to that of M2.13 In brief, a catalytic amount of NaHCO3 (1.3 mg, 0.015 mmol) was added to a mixture of 8S (91.2 mg, 0.3 mmol) and cysteine (54 mg, 0.45 mmol) in methanol/water (6 mL, 1:1, v/v). The mixture was then stirred at room temperature for 24 h, and adjusted to pH 6 with a diluted acetic acid solution (0.1 M). The mixture was then purified by preparative HPLC to give M2’ as a white solid (70 mg, yield 55%). Shogaol 10S (100 mg, 0.3 mmol) instead of 8S was used in the above reaction to give M2″ (73 mg, yield 54%).

Purification of M2’ or M2″ Using Preparative HPLC. Waters preparative HPLC systems with 2545 binary gradient module, Waters 2767 sample manager, Waters 2487 UV/Visible flow cell, Waters fraction collector III, dual injector module, and 2489 UV/Visible detector were used to separate M2’ or M2″ from the reaction mixture. A Phenomenex Gemini-NX C18 column (250 mm × 3.0 mm i.d., 5 μm) was used with a flow rate of 20.0 mL/min. The wavelength of the UV detector was set at 280 nm. The injection volume was 1.0 mL for each run. The mobile phase consisted of solvent A (H2O + 0.1% formic acid) and solvent B (MeOH + 0.1% formic acid). The reaction mixture of M2’ was injected to the preparative column and eluted with a gradient solvent system (75% to 87% B from 0 to 12 min; to 75% B from 12 to 12.5 min; then 75% B from 12.5 to 15 min). A total of six runs resulted in 70 mg of M2’ (tR 9.45 min). Similarly, reaction mixture of M2″ was injected to the preparative column and eluted with a gradient solvent system (85% to 100% B from 0 to 15 min; then...
cells were cultured in McCoy s 5A medium. All of the above media were diluted in McCoy s 5A medium. Oa. 1% NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, Thermo Fisher Scientific supplemented with a protease inhibitor cocktail (AEBSF, aprotinin, benztain, E-64, leupeptin, and pepstatin A in DMSO with EDTA, Thermo Fisher Scientific). Protein content was measured by a Pierce BCA Assay Kit (Thermo Fisher Scientific). Protein contents of cell lysates (30 μg of protein/lane) were resolved by SDS-PAGE. Proteins were then electro-transferred onto PVDF membranes, and blots were blocked for 1 h at room temperature in 1 X TBS with 1% casein (Bio-Rad Laboratories, Berkeley, CA). Blots were then incubated overnight at 4 °C with the desired primary antibody diluted in TBS with 0.5% Tween 20. Blots were then washed with TBS-Tween 20 and probed for 1 h with the appropriate secondary antibody (1:1000). Protein bands were visualized with chemiluminescence using West Femto maximum detection substrate (Thermo Fisher Scientific). To confirm equal protein loading in each lane, immunoblots were stripped and reprobed for β-actin. Protein fold-induction was calculated by normalizing the intensity of the band of interest to β-actin first and then to DMSO control lanes.

**Colony Formation Assay.** Human colon cancer cells HCT-116 or HT-29 (1000 cells per well) were seeded in 6-well culture plates for 24 h and then incubated with M2 (0, 1, 5, 10, 20, or 40 μM) in DMSO in a 37 °C incubator with 5% CO2. After 2 weeks, colonies were washed with phosphate-buffered saline (PBS), then stained with a mixture of 0.60% glutaraldehyde and 0.5% crystal violet for 30 min at room temperature, rinsed in water, air-dried, and then photographed.

**Statistical Analysis.** Student’s t-test or two-way analysis of variance (ANOVA) with the Bonferroni post-test were used to determine the statistical significance of data, which was performed on GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego, CA).

### RESULTS

**Synthesis and Structure Elucidation of M2’ and M2**.

A similar experimental procedure was used for the syntheses of M2’ and M2 as the previous protocol used for M2.3 M2 showed the molecular formula C_{m+1}H_{n+2}NO_{S} on the basis of positive ESI-MS at m/z 426 [M + H]+ and its 1H and 13C NMR data. The molecular weight of M2’ was 121 mass units more than that of 8S (MW 304), indicating that M2’ was the cysteine-conjugated 8S, which is an expected result from the reaction between 8S and l-cysteine. This was also supported by the observation of the absence of a double bond in the 1H and 13C NMR spectra of M2’. Therefore, M2’ was confirmed to be 5-cysteinyl-8S. In the same way, M2’ was identified as 5-cysteinyl-10S, based on its positive ESI-MS at m/z 454 [M + H]+ and its 1H and 13C NMR data (Table 1).

M2’ and M2 Give Similar Metabolic Profiles as Their Parent Compounds 8S and 10S. Recent work in our group has focused on the biotransformation of the cysteine-conjugated metabolite of 6S, M2. The metabolic profiles of M2 in cancer cells HCT-116 and H-1299 resembled those of 6S, indicating that its biotransformation route was initiated by deconjugation.23 Evidence supporting the identification of M2’ and M2 as carriers of their respective shogaols is presented in
Figure 1, in which the metabolic profiles of 8S and 10S in human colon fibroblast cells CCD18Co (Figure 1C,F) or human colon cancer cells HCT-116 (Figure 1D,G) and HT-29 (Figure 1E,H) are compared with the profiles of M2′ and M2″ in the same respective cell lines. Upon removal of the cysteine residue, which occurs after less than 2 h of treatment, M2′ and M2″ are metabolized in an almost identical fashion as their parent shogaols. We have reported that M9 and M11 are the major metabolites of 6S in cancer cells; M11 is the double bond reduced metabolite of 6S, and M9 is the ketone group reduced metabolite of M11.19 In the present study, reduced products were also identified as the major metabolites of 8S and 10S in human colon fibroblast cells and cancer cells, M9′ and M11′ for 8S and M9″ and M11″ for 10S. Their structures were confirmed by comparing their MS/MS spectra with those of M9 and M11 (Figure 2).

M2′ and M2″ Exert Similar Bioactivities as Their Parent Compounds 8S and 10S. We have reported that M2 has low toxicity in normal human fibroblast colon and lung cells while still remaining toxic against colon cancer and lung cancer cells.13 As the structure of the cysteine-conjugated metabolites of 8S and 10S only differ from 6S by their respective increases in side chain length, we hypothesized that M2′ and M2″ should have similar activities compared with their parent molecules as M2 has compared with 6S.

Our results from measurement of cell viability by MTT assay show that 8S and 10S and their respective cysteine-conjugated metabolites M2′ and M2″ have low toxicity in normal colon cells CCD-18Co (Figure 3A), with IC_{50} values of 104.66 and 135.53 μM for 8S and 10S, respectively, and IC_{50} values greater than 200 μM for M2′ and M2″. All compounds were highly potent against human colon cancer cells HCT-116 (Figure 3B) and HT-29 (Figure 3C), with slightly different efficacy profiles between the two types of cells. M2′ and M2″ show higher activity against HCT-116 than their parent molecules, with IC_{50} values of 15.21 and 13.28 μM, respectively, versus values of 22.8 and 25.09 μM for 8S and 10S, respectively. Similar results were observed in the p53 mutant HT-29 cell line, albeit slightly more resistant to treatment from all compounds. The IC_{50} values for 8S and 10S, 27.88 and 23.92 μM, were about 10–16% lower than those for M2′ and M2″, at 31.15 and 28.75 μM, respectively.

M2 Induces Apoptosis in Human Colon Cancer Cells HCT-116 and HT-29. In order to compare the biological similarities of M2, M2′, and M2″, we first needed to acquire a more accurate view of the mechanisms of action of M2. To study the impact of M2 on induction of apoptosis in both HCT-116 and HT-29 colon cancer cells, the percent of apoptotic cells were quantified after 24 h treatment of increasing doses of M2 (Figure 3D). A dose-dependent effect of M2 was observed with HCT-116 cells being notably more sensitive to M2 treatment than HT-29 cells. Treatment with 40 μM M2 gave the greatest induction of apoptosis in HCT-116 and HT-29 cells, with 26.34% or 14.38% apoptotic cells, respectively. The 10 and 20 μM treatments also yielded twice as many apoptotic HCT-116 cells compared with HT-29 cells (Figure 3D).
Induction of apoptosis was further confirmed by Western blot analysis of markers of the intrinsic mitochondrial apoptosis pathway (Figure 3E). Increasing doses of M2 led to PUMA induction (up to ∼17-fold increase in both cell lines when treated with 40 μM M2) and progressive reduction of Bcl-2 levels (undetectable in HCT-116 and ∼0.1-fold in HT-29 cells when treated with 40 μM M2). We detected a progressive increase in cytochrome c release with increasing doses of M2 (up to ∼2.2-fold increase in both cell lines when treated with 40 μM M2). We also observed a clear, progressive reduction in XIAP expression with increasing doses of M2 (undetectable in HCT-116 and ∼0.3-fold in HT-29 cells when treated with 40 μM M2). Finally, increasing concentration of the cleaved forms of caspase 9 (up to ∼4.6-fold increase in both cell lines when treated with 40 μM M2) and caspase 3 (up to ∼4-fold increase in both cell lines when treated with 40 μM M2) were detected with increasing doses of M2. Overall, these results show that markers of the mitochondrial pathway (PUMA, Bcl-2) of apoptosis were activated upon exposure to M2 and ultimately led to the release of the corresponding apoptosis markers (cytochrome c, cleaved caspases 3 and 9).

8S, 10S, M2′, and M2″ Activate Apoptosis. Our results on M2′ and M2″ are consistent with our previous observation that M2 has low toxicity in normal colon cells while still retaining strikingly similar potency to 6S in cancer cell growth inhibition.13 Thus, we could tentatively propose that M2′ and M2″ have similar biological roles as the function we previously proposed for M2, as low toxicity carriers of parent molecular 8S and 10S to active sites, where function is restored upon removal of the cysteine group.23 To verify this hypothesis, we studied the apoptotic markers modulated by M2 (described Figure 3E) in HCT-116 and HT-29 cells treated with 8S, M2′, 10S, or M2″ for 24 h. We chose a dose of 20 μM since it is close to the IC_{50} values of all compounds.

Screening of the markers modulated by the pro-apoptotic activity of M2 gave similar results for 8S and 10S and their respective cysteine-conjugated metabolites M2′ and M2″ (Figure 4A). In other words, PUMA and cleaved caspase-3 were up-regulated, with concomitant down-regulation of Bcl-2. The changes in marker expression was observed in both cell lines in a nearly identical amplitude between the parent compound and its corresponding metabolite.

Shogaols and Their Cysteine-Conjugated Metabolites Affect Wild-Type and Mutant p53 Expression in Human Colon Cancer Cells HCT-116 and HT-29. Since we established that the cysteine-conjugated shogaols could activate apoptosis through the same pathway, we wanted to further study their mechanisms of action using 6S and its metabolite M2 as a model. We established that PUMA, a transcriptional target of p53, accumulated almost identically in p53 wild-type...
HCT-116 and p53 mutant HT-29 cell lines, with both showing greater than 17-fold induction of PUMA after 24 h treatment with 40 μM M2 (Figure 3E). To study the impact of M2 on p53 regulation in human colon cancer cells and its dependency on p53 integrity, p53 wild-type HCT-116 or p53 mutant HT-29 cells were cultured with M2 or 6S for 24 h at concentrations of 10, 20, or 40 μM. The p53 response in colon cancer cells to 6S treatment (10, 20, or 40 μM for 24 h) was observed in HCT-116 and HT-29. After M2 or 6S treatment, a dose-dependent up-regulation of p53 is noted in both wild-type and mutant cancer cell lines (Figure 4B,C), indicating that M2 or 6S regulation of p53 does not require a wild-type gene, although induction of p53 expression by M2 or 6S is dramatic in HCT-116 cells and slightly less striking (but still significant) in HT-29 cells (Figure 4B,C). Consistent with our premise, we then studied p53 expression in HCT-116 and HT-29 cells after exposure to 20 μM of 8S, M2, 10S, or M2’. We observed an increase in p53 accumulation for all compounds (Figure 4A). The cysteine-conjugated metabolites were able to increase p53 accumulation in a similar manner to their parent compound.

6S and Its Cysteine-Conjugated Metabolite M2 Affect Reactive Oxygen Species Generation in Human Colon Cancer Cells HCT-116 and HT-29. Our observations up to this point indicated that M2 induces apoptosis in colon cancer cells through modulation of p53 expression and subsequent activation of the mitochondrial apoptotic pathway through PUMA and Bcl-2. However, the mechanism triggering the p53 accumulation was still unclear. Because overabundance of reactive oxygen species has been implicated as a genotoxic stressor and trigger for p53 activation,29–33 we observed the production of ROS by M2 (compared with parent compound 6S for reference) in HCT-116 and HT-29 cells. As shown in Figure 4D,E, the trends of ROS induction by both M2 and 6S are strikingly similar, with the greatest peak at 2 h after treatment and a steady decline thereafter, which is consistent with the changes of glutathione levels in cancer cells that we reported previously.23 In this case, treatment of HCT-116 cells with 40 μM M2 produced the greatest ROS activity after 2 h, with greater than 2-fold induction (with statistical significance, \( p < 0.0001 \)). The scales of induction of ROS by M2 or 6S are parallel to the p53 induction response in the two respective cell lines. That is, in HCT-116 cells, ROS activity is induced 2-fold or greater by M2 or 6S treatment, while in HT-29 cells, ROS activity is induced less than 1.5-fold.

To demonstrate that ROS induction was indeed the trigger to p53 accumulation, we treated HCT-116 and HT-29 cells with M2 or 6S (10, 20, or 40 μM) and supplemented with 5 mM GSH in order to suppress ROS accumulation in the cells. As shown on Figure 4B,C, addition of GSH suppressed p53 induction in both cell lines for all concentrations of M2 or 6S, establishing that p53 does not accumulate if there is no ROS generation.

M2 Inhibits Colony Formation in Human Colon Cancer Cells HCT-116 and HT-29. While we established that the cysteine conjugate of 6S can activate apoptosis, it is possible that other mechanisms leading to cancer cell death are triggered, especially in light of the specific activation of the multiacting p53. Since p53 is one of the major regulators of the
cell cycle, we further investigated the potential of our cysteine conjugated metabolites to inhibit cancer cell proliferation, using a colony assay and M2 as a model. Human colon cancer cells HCT-116 (Figure 5A) and HT-29 (Figure 5B) were treated with M2 with doses ranging from 0 to 40 μM for 2 weeks. Inhibition of colony formation was observed in a dose-dependent manner in both cell lines, with 50% inhibition between 5 and 10 μM treatments. Following a trend underlined previously, HCT-116 cells are slightly more sensitive to M2 than HT-29 cells.

**DISCUSSION**

There is currently considerable interest in developing cancer therapeutics and preventive agents from dietary sources, with extensive research over the past few decades focusing on plant derivatives. Ginger has been comprehensively studied in recent years for its chemopreventive properties, particularly against colorectal cancer. Our group and others have identified active constituents of ginger, with our most recent focus on shogaols, especially 6S. The metabolism and biotransformation of 6S was investigated thoroughly, providing further insight into its means of exerting bioactivity. Upon testing the efficacy of the major metabolites of 6S, we found that 5-cysteinyl-conjugated 6S (M2) exerted strong antiproliferative activity against human colon cancer cells, while having significantly lessened toxicity in normal human colon cells. Further, M2 was shown to act as a carrier of parent molecule 6S. The discovery of M2 was via correlation of 6S metabolism as a highly electrophilic xenobiotic through the detoxifying mercapturic acid pathway (MAP). We also found that increased chain length of shogaols does not cause a departure from the MAP. M2' and M2" were identified as the major metabolites of 8S and 10S, respectively, from humans upon consumption of ginger tea. The current study shows that M2' and M2" are the carriers of 8S and 10S, respectively, and have similar antiproliferative activity against human colon cancer cells and less toxicity in normal human colon cells to their respective parent compounds. Our results clearly indicate that this portion of phase II metabolism transforms electrophiles to less reactive and more water-soluble intermediates, thus aiding in their mobility and decreasing their toxicity en route.

It has already been established through many studies that 6S induces apoptosis in cancer cells via several pathways, and thus our focus was to identify the pathway that encompasses the mode of activity of M2. We demonstrated that M2 treatment could induce ROS generation, which in turn up-regulated p53 expression and induced apoptosis through the mitochondrial pathway. This proposed mechanism is summarized in Figure 6. Since tumor suppressor gene p53 is one of the most frequent mutations in cancers, leading to resistance to pharmacological interventions and more aggressive progression, we were interested in testing the efficacy of M2 in wild-type p53 HCT-116 human colon cancer cells as well as mutant p53 HT-29 human colon cancer cells. In what could be a fortunate outcome for the putative roles of ginger constituents and metabolites toward chemoprevention, M2 induced apoptosis in both cell lines. It is notable that although the p53 pro-apoptotic pathway was exploited for at least some of M2’s bioactivity and that we observed a general trend of superior bioactivity in HCT-116 cells, the metabolite’s efficacy was ultimately not compromised by p53 mutation. This is particularly attractive in terms of cancer chemoprevention, since it suggests that the cysteine-conjugated metabolite of 6S would still be able to activate a p53 apoptotic response even in cancer cells containing mutations of the p53 gene.
A commonly proposed p53-induced apoptosis mechanism involves direct interaction with Bcl-2 family members and down-regulation of antiapoptotic genes, such as Bcl-2, which was also noted in the current study. Both HCT-116 and HT-29 human colon cancer cells experienced a dramatic down-regulation of Bcl-2 after M2 treatment. Interestingly, PUMA, a transcriptional target of p53, was also up-regulated in both colon cancer cell lines after treatment with M2. Upon a transcriptionally induced signal from p53, PUMA assists in promoting apoptosis by disrupting the association restraints Bcl-xL exerts on p53, thus liberating the molecule to exert pro-apoptotic activity, but binding to Bcl-xL in the process. This evidence supports the strong role of M2 as a chemopreventive agent against colon cancer cells that induces p53 expression and downstream regulation.

Treatment of colon cancer cells HCT-116 and HT-29 with M2 in this study lead to apoptosis, through early production of reactive oxygen species. Overabundance of ROS combined with a cancer cell’s reduced detoxification ability can often lead to oxidative stress sufficient to induce programmed cell death. Apoptosis induced by p53 is at least partially dependent upon accumulation of ROS, and we demonstrated this to be also true in our model. Therefore, we can conclude that M2 causes p53 induction of apoptosis via ROS production in both HCT-116 and HT-29 human colon cancer cells. Since we demonstrated that the other metabolites M2’ and M2” activate similar markers of apoptosis (Figure 4A) and contain the same chemical reactivity as M2, it is reasonable to conclude that these metabolites would behave in a similar way and could also activate cancer cell apoptosis through ROS induction and the subsequent p53 accumulation. In addition, we also demonstrated that M2 does not exclusively induce cancer cell death through apoptosis and can also influence other major mechanisms such as cell proliferation (Figure 5); it follows that other cysteine conjugated metabolites originating from the same MAP have that potential as well. These compounds are worthy of further investigation, and further studies could examine commonly consumed ginger mixtures containing these compounds for more direct translation of these data to in vivo dietary models.

Ginger components are highly lauded for their vast and varied chemopreventive properties. Because shogaols have been proven as highly effective anticancer agents, the continued study of their mechanisms of activity can allow us to discover novel anticancer targets. Further, investigation of the metabolic products of shogaols can provide new therapeutic routes that are less toxic, while retaining high efficacy. This study has shown that cysteine-conjugated shogaols are novel compounds...
with a putative role as natural pharmaceuticals with low-toxicity, high-potency, and at least partial indifference to p53 integrity in colon cancer cells.

**AUTHOR INFORMATION**

*Corresponding Author*
*Tel: 704-250-5710. Fax: 704-250-5709. E-mail: ssang@ncat.edu.*

**Author Contributions**

$^2$H.C. and D.N.S. contributed equally to this work.

**Notes**

The authors declare no competing financial interest.

**ACKNOWLEDGMENTS**

This work was supported by NIH Grants CA138277 and CA138277/S1 to S. Sang.

**ABBREVIATIONS**

6S, [6]-shogaol; 8S, [8]-shogaol; 10S, [10]-shogaol; GSH, glutathione; HPLC, high-performance liquid chromatography; LC/MS, liquid chromatography/mass spectrometry; M2, S-cysteiny1-6S; M2’, S-cysteinyl-8S; M2”, S-cysteinyl-10S; p53, tumor protein 53; ROS, reactive oxygen species

**REFERENCES**

(1) Park, E. J.; Pezzuto, J. M. Botanicals in cancer chemoprevention. *Cancer Metastasis Rev.* **2002**, *21*, 231–255.

(2) Kubra, I. R.; Rao, L. J. An impression on current developments in the technology, chemistry, and biological activities of ginger (*Zingiber officinale Roscoe*). *Crit. Rev. Food Sci. Nutr.* **2011**, *52*, 651–688.

(3) Ali, B. H.; Blunden, G.; Tanira, M. O.; Nemmar, A. Some phytochemical, pharmacological and toxicological properties of ginger (*Zingiber officinale Roscoe*): A review of recent research. *Food Chem. Toxicol.* **2008**, *46*, 409–420.

(4) Altman, R. D.; Marcusen, K. C. Effects of a ginger extract on knee pain in patients with osteoarthritis. *Arthritis Rheum.* **2001**, *44*, 2531–2538.

(5) Lantz, R. C.; Chen, G. J.; Sarlah, M.; Solyom, A. M.; Jolad, S. D.; Timmermann, B. N. The effect of extracts from ginger rhizome on inflammatory mediator production. *Phytomedicine* **2007**, *14*, 123–128.

(6) Kim, J. S.; Lee, S. I.; Park, H. W.; Yang, J. H.; Shin, T. Y.; Kim, Y. C.; Baek, N. I.; Kim, S. H.; Choi, S. U.; Kwon, B. M.; Leem, K. H.; Jung, M. Y.; Kim, D. K. Cytotoxic components from the dried rhizomes of *Zingiber officinale Roscoe*. *Arch Pharm. Res.* **2008**, *31*, 415–418.

(7) Bak, M. J.; Ok, S.; Jun, M.; Jeong, W. S. 6-Shogaol-rich extract from ginger up-regulates the antioxidant defense systems in cells and mice. *Molecules* **2012**, *17*, 8037–8053.

(8) Dugasani, S.; Pichika, M. R.; Narada, V. D.; Balijepalli, M. K.; Tanda, S.; Korlakunta, J. N. Comparative antioxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, [10]-gingerol and [6]-shogaol. *J. Ethnopharmacol.* **2010**, *127*, 515–520.

(9) Wu, H.; Hsieh, M. C.; Lo, C. Y.; Liu, C. B.; Sang, S.; Ho, C. T.; Pan, M. H. 6-Shogaol is more effective than 6-gingerol and curcumin in inhibiting 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. *Mol. Nutr. Food Res.* **2010**, *54*, 1296–1306.

(10) Sang, S.; Hong, J.; Wu, H.; Liu, J.; Yang, C. S.; Pan, M. H.; Badmaev, V.; Ho, C. T. Increased growth inhibitory effects on human cancer cells and anti-inflammatory potency of shogaols from *Zingiber officinale* relative to gingerols. *J. Agric. Food Chem.* **2009**, *57*, 10645–10650.

(11) Siegel, R.; Ward, E.; Brawley, O.; Jemal, A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *Cancer J. Clin.* **2011**, *61*, 212–36.

(12) Tan, B. S.; Kang, O.; Mai, C. W.; Tiong, K. H.; Khoo, A. S.; Pichika, M. R.; Bradshaw, T. D.; Leong, C. O. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor gamma (PPARgamma). *Cancer Lett.* **2013**, *336*, 127–39.

(13) Zhu, Y.; Warin, R. F.; Soroka, D. N.; Chen, H.; Sang, S. Metabolites of ginger component [6]-shogaol remain bioactive in cancer cells and have low toxicity in normal cells: chemical synthesis and biological evaluation. *PloS One* **2013**, *8*, e54677.

(14) Gan, F. F.; Nagle, A. A.; Ang, X.; Ho, O. H.; Tan, S. H.; Yang, H.; Chui, W. K.; Chew, E. H. Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation. *Aggressology* **2011**, *16*, 856–867.

(15) Pan, M. H.; Hsieh, M. C.; Kuo, J. M.; Lai, C. S.; Wu, H.; Sang, S.; Ho, C. T. 6-Shogaol induces apoptosis in human colorectal carcinoma cells via ROS production, caspase activation, and GADD 153 expression. *Mol. Nutr. Food Res.* **2008**, *52*, 527–537.

(16) Bansal, P.; Khoochbchandani, M.; Kumar, V.; Srivastava, M. M., Cruciferous Vegetables: Novel Cancer Killer and Guardians of Our Health. *In Chemistry of Phytotoxins: Health, Energy and Environmental Perspectives*, Khemani, L. D., Srivastava, M. M., Srivastava, S., Eds.; Springer: Berlin Heidelberg, 2012; pp 3–7.

(17) Tan, X.-L.; Spivack, S. D. Dietary chemoprevention strategies for induction of phase II xenobiotic-metabolizing enzymes in lung carcinogenesis: A review. *Lung Cancer* **2009**, *65*, 129–137.

(18) Zhang, Y. Allyl isothiocyanate as a cancer chemopreventive phytochemical. *Mol. Nutr. Food Res.* **2010**, *54*, 127–135.

(19) Chen, H.; Lv, L.; Soroka, D.; Warin, R. F.; Parks, T. A.; Hu, Y.; Zhu, Y.; Chen, X.; Sang, S. Metabolism of [6]-shogaol in mice and in cancer cells. *Drug Metab. Dispos.* **2012**, *40*, 742–753.

(20) Chen, H.; Sang, S. Identification of phase II metabolites of thiol-conjugated [6]-shogaol in mouse urine using high-performance liquid chromatography tandem mass spectrometry. *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.* **2012**, *907*, 126–139.

(21) Chen, H.; Soroka, D. N.; Hu, Y.; Chen, X.; Sang, S. Characterization of thiol-conjugated metabolites of ginger components shogaols in mouse and human urine and modulation of the glutathione levels in cancer cells by [6]-shogaol. *Mol. Nutr. Food Res.* **2013**, *57*, 447–458.

(22) Conaway, C. C.; Kozeminski, J.; Amin, S.; Chung, F. L. Decomposition rates of isothiocyanate conjugates determine their activity as inhibitors of cytochrome p450 enzymes. *Chem. Res. Toxicol.* **2001**, *14*, 1170–1176.

(23) Chen, H.; Soroka, D. N.; Zhu, Y.; Hu, Y.; Chen, X.; Sang, S. Cysteine-conjugated metabolite of ginger component [6]-shogaol serves as a carrier of [6]-shogaol in cancer cells and in mice. *Chem. Res. Toxicol.* **2013**, *26*, 976–985.

(24) Soussi, T.; Lozano, G. p53 mutation heterogeneity in cancer. *Biochem. Biophys. Res. Commun.* **2005**, *331*, 834–842.

(25) Toledo, F.; Wahl, G. M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. *Nat. Rev. Cancer* **2006**, *6*, 909–923.

(26) Seemann, S.; Maurici, D.; Olivier, M.; Caron de Fromentel, C.; Hainaut, P. The tumor suppressor gene TP53: Implications for cancer management and therapy. *Crit. Rev. Clin. Lab. Sci.* **2004**, *41*, 551–583.

(27) Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. *J. Immunol. Methods* **1983**, *65*, S5–63.

(28) Brandt, R.; Keston, A. S. Synthesis of diacetyldichlorofluorescin: A stable reagent for fluorometric analysis. *Anal. Biochem.* **1965**, *11*, 6–9.

(29) Qin, H.; Yu, T.; Qing, T.; Liu, Y.; Zhao, Y.; Cai, J.; Li, J.; Song, Z.; Qu, X.; Zhou, P.; Wu, J.; Ding, M.; Deng, H. Regulation of apoptosis and differentiation by p53 in human embryonic stem cells. *J. Biol. Chem.* **2007**, *282*, 584–582.

(30) Speidel, D.; Helmbold, H.; Deppert, W. Dissection of transcriptional and non-transcriptional p53 activities in the response to genotoxic stress. *Oncogene* **2006**, *25*, 940–953.

(31) Tao, Y.; Li, W.; Liang, W.; Van Breenen, R. B. Identification and quantification of gingerols and related compounds in ginger dietary supplements using high-performance liquid chromatography-
tandem mass spectrometry. *J. Agric. Food Chem.* **2009**, *57*, 10014–10021.

(32) Waster, P. K.; Ollinger, K. M. Redox-dependent translocation of p53 to mitochondria or nucleus in human melanocytes after UVA- and UVB-induced apoptosis. *J. Invest. Dermatol.* **2009**, *129*, 1769–1781.  

(33) Zhao, Y.; Chaiswing, L.; Velez, J. M.; Batinic-Haberle, I.; Colburn, N. H.; Oberley, T. D.; St Clair, D. K. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. *Cancer Res.* **2005**, *65*, 3745–3750.  

(34) Cerella, C.; Radogna, F.; Dicato, M.; Diederich, M. Natural compounds as regulators of the cancer cell metabolism. *Int. J. Cell Biol.* **2013**, *2013*, No. 639401.  

(35) Cohen, S.; Flescher, E. Methyl jasmonate: A plant stress hormone as an anti-cancer drug. *Phytochemistry* **2009**, *70*, 1600–1609.  

(36) Elkady, A. I.; Abuzinadah, O. A.; Baeshen, N. A.; Rahmy, T. R. Differential control of growth, apoptotic activity, and gene expression in human breast cancer cells by extracts derived from medicinal herbs *Zingiber officinale*. *J. Biomed. Biotechnol.* **2012**, *2012*, No. 614356.  

(37) Karna, P.; Chagani, S.; Gundala, S. R.; Rida, P. C.; Asif, G.; Sharma, V.; Gupta, M. V.; Aneja, R. Benefits of whole ginger extract in prostate cancer. *Br. J. Nutr.* **2012**, *107*, 473–484.  

(38) Ohiková, B.; Diederich, M. Power from the garden: Plant compounds as inhibitors of the hallmarks of cancer. *Curr. Med. Chem.* **2012**, *19*, 2061–2087.  

(39) Stoner, G. D. Ginger: Is it Ready for Prime Time? *Cancer Prev. Res.* **2013**, *6*, 257–262.  

(40) Citronberg, J.; Bostick, R.; Ahearn, T.; Turgeon, D. K.; Ruffin, M. T.; Djuric, Z.; Sen, A.; Brenner, D. E.; Zick, S. M. Effects of Ginger Supplementation on Cell-Cycle Biomarkers in the Normal-Appearing Colon. *Curr. Med. Chem.* **2012**, *19*, 271–281.  

(41) Yogosawa, S.; Yamada, Y.; Yasuda, S.; Sun, Q.; Takizawa, K.; Sakai, T. Dehydrozingerone, a structural analogue of curcumin, induces cell-cycle arrest at the G2/M phase and accumulates intracellular ROS in HT-29 human colon cancer cells. *J. Nat. Prod.* **2012**, *75*, 2088–2093.  

(42) Ramos, S. Cancer chemoprevention and chemotherapy: Dietary polyphenols and signalling pathways. *Mol. Nutr Food Res.* **2008**, *52*, 507–526.  

(43) Park, G.; Kim, H. G.; Ju, M. S.; Ha, S. K.; Park, Y.; Kim, S. Y.; Oh, M. S. 6-Shogaol, an active compound of ginger, protects dopaminergic neurons in Parkinson’s disease models via anti-neuroinflammation. *Acta Pharmacol. Sin.* **2013**, *34*, 1131–1139.  

(44) Chen, H.; Soroka, D.; Zhu, Y.; Sang, S. Metabolism of ginger component [6]-shogaol in liver microsomes from mouse, rat, dog, monkey, and human. *Molecular Nutr. Food Res.* **2013**, *57*, 865–876.  

(45) Xu, C.; Li, C.-T.; Kong, A.-N. Induction of phase I and II and III drug metabolism/transport by xenobiotics. *Arch. Pharmacol. Res.* **2005**, *28*, 249–268.  

(46) Wang, B.; Xiao, Z.; Ko, H. L.; Ren, E. C. The p53 response element and transcriptional repression. *Cell Cycle (Georgetown, Tex.)* **2010**, *9*, 870–879.  

(47) Vousden, K. H.; Prives, C. Blinded by the Light: The Growing Complexity of p53. *Cell* **2009**, *137*, 413–431.  

(48) Lane, D.; Levine, A. p53 Research: The past thirty years and the next thirty years. *Cold Spring Harbor Perspect. Biol.* **2010**, *2*, No. a000893.  

(49) Garrattato, S.; Inga, A.; Gemignani, F.; Landi, S. More targets, more pathways and more clues for mutant p53. *Oncogene* **2013**, *2*, No. e54.  

(50) Laptenko, O.; Prives, C. Transcriptional regulation by p53: One protein, many possibilities. *Cell Death Differ.* **2006**, *13*, 951–961.  

(51) Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. . *Nat. Rev. Drug Discovery* **2008**, *7*, 979–987.